Police agencies worldwide seized $65 million (€57.2 million) worth of counterfeit or unapproved medicines in a major ...

Indian pharma catching up to Ozempic, Mounjaro demand Indian market for these drugs has grown to nearly Rs 600 crore and is expected to keep growing. Weight-loss drugs are transforming India's ...

In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that, amidst ...

Besides Mankind, Natco Pharma, Dr Reddy’s, Sun Pharma and others are already gearing up for launches of weight-loss drugs like Ozempic and Wegovy, which are going off patent in India in January 2026 ...

Learn about Ozempic (semaglutide) microdosing for weight loss, ... Ozempic pen (strength) Typical dose, once weekly Intermediate doses, once weekly Number of clicks; 0.25 and 0.5 mg (2 mg/3 mL) ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite missing the company’s initial sales expectations. Novo Nordisk (NVO), the ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of potentially devastating side effects and can also trap users on an endless ...

Despite setting the Ozempic rumours straight, Lizzo still found herself under scrutiny - this time for her unusual way of holding a pen, which sparked some online roasting.

HEALTH-WEIGHTLOSS/CHINA (INSIGHT, PIX):INSIGHT-How Asian pharma suppliers cash in on Ozempic copies. Reuters. Published 1 Nov 2024, 05:32 AM IST.

Ozempic was developed for type 2 diabetes but its active ingredient semaglutide is effective in promoting weight loss. The market for such weight-loss treatments, which Novo Nordisk is targeting with ...

Bangladeshi drugs made with Ozempic key ingredient shipped to 12 markets, including U.S. and Britain - data Novo Nordisk says it cannot vouch for safety of unapproved semaglutide-based products ...

Just over a year ago, New Zealand customs officials started to intercept batches of injectable medications labelled Fitaro and Orsema, developed by a little-known Bangladeshi drugmaker, Incepta ...